Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effusions and pericardial effusion that has not previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulhoi, Maiken Parm, Sorensen, Boe Sandahl, Meldgaard, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525301/
https://www.ncbi.nlm.nih.gov/pubmed/34720935
http://dx.doi.org/10.1159/000518081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525301/
https://www.ncbi.nlm.nih.gov/pubmed/34720935
http://dx.doi.org/10.1159/000518081

Ejemplares similares